Brief: TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
08/09/2025 12:42
Sept 8 (Reuters) - TG Therapeutics Inc TGTX.O: TG ANNOUNCES PHASE 3 TRIAL FOR SUBCUTANEOUS BRIUMVI COMMENCED ENROLLMENT Source text: ID:nGNX80ckzw Further company coverage: TGTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on TG Therapeutics
See all newsTG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj